#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neoplasm malignant Breast angiosarcoma Acute graft versus host disease in liver Vaginal cancer Vascular malformation Juvenile psoriatic arthritis Encephalopathy neonatal Acute hepatic failure Leukocyte adhesion deficiency Fabry's disease Chronic graft versus host disease in intestine Systemic lupus erythematosus Prolymphocytic leukaemia Autoimmune hepatitis Acute lymphocytic leukaemia recurrent More trials…

    Learn about Rare Diseases

    X-linked lymphoproliferative syndrome Progressive multifocal leukoencephalopathy – Basic Information Synovial sarcoma metastatic – Diagnostics Familial amyotrophic lateral sclerosis – Trials in Disease Mast cell activation syndrome – Diagnostics KBG syndrome Waldenstrom’s macroglobulinaemia refractory – Life with Disease Uterine leiomyosarcoma – Treatment Isodicentric chromosome 15 syndrome – Diagnostics Extranodal marginal zone B-cell lymphoma (MALT type) – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Oxygen Ph.eur. SILYMARIN Zasocitinib Mifepristone GSKVX000000070248 SURVODUTIDE Tak-280 Ulipristal Acetate Palonosetron Potassium Iodide Ampreloxetine Trastuzumab Emtansine Gadobutrol Sertraline Hydrochloride Dutasteride Cinchocaine Hydrochloride Paroxetine Hydrochloride Human Coagulation Factor Vii Izokibep M-(18F)-Fluorobenzylguanidine More therapies…

    Learn about Your Condition

    Laparotomy Hepatoblastoma Septic shock Factor VIII deficiency Behcet's syndrome Oesophagectomy Gastrectomy Post-traumatic headache Gastrooesophageal cancer Behavioural addiction Prostate cancer recurrent Desmoplastic melanoma Cystic fibrosis lung Acute cardiac event Craniotomy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Spinal muscular atrophy

  • Study of Apitegromab Treatment in Children Under 2 Years Old with Spinal Muscular Atrophy (SMA)

    Recruiting

    2 1 1
    Investigated Drugs:
    • Apitegromab
    Belgium France Italy The Netherlands Spain

  • Study on the Early Use of Risdiplam for Children with Spinal Muscular Atrophy After Gene Therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Risdiplam
    Germany Poland

  • Study on the Effectiveness and Safety of Risdiplam for Children with Spinal Muscular Atrophy After Gene Therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Risdiplam
    Germany Poland

  • Safety and Efficacy of Intrathecal BIIB115 in Infants with Spinal Muscular Atrophy Previously Treated with Onasemnogene Abeparvovec

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Spinal muscular atrophy
    Investigated Drugs:
    • BIIB115
    Belgium Croatia France Germany Hungary Ireland +4

  • Study of BIIB115 in patients aged 15‑60 years with spinal muscular atrophy who are treatment‑naïve or previously treated with risdiplam

    Not yet recruiting

    3 1 1
    Investigated Drugs:
    • BIIB115
    Finland France Germany Ireland Italy Poland +1

  • Study on the Safety and Tolerability of BIIB115 for Children with Spinal Muscular Atrophy Previously Treated with Gene Therapy

    Not recruiting

    1 1
    Investigated Diseases:
    • Spinal muscular atrophy
    Investigated Drugs:
    • BIIB115
    Belgium France Germany Italy The Netherlands Poland
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!